Komen Debuts New Websites on Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 12
Volume 6
Issue 12

DALLAS-The Susan G. Komen Breast Cancer Foundation, known for raising awareness and community support for breast cancer research and programs through its Race for the Cure, has unveiled three new websites that form a comprehensive online source of breast health and breast cancer information.

DALLAS—The Susan G. Komen Breast Cancer Foundation, known for raising awareness and community support for breast cancer research and programs through its Race for the Cure, has unveiled three new websites that form a comprehensive online source of breast health and breast cancer information.

“We’ve developed a sound source of trusted information that can be tapped into anytime, day or night,” said Nancy Brinker, founding chairman of the Komen Foundation. “And we’ve gone a step further by providing people the ability to share their personal experiences on our websites, creating a sense of empowerment and community spirit online.”

Internet users can access the websites by using one of three Internet addresses: (1) www.breastcancerinfo.com, (2) www.raceforthecure.com, and (3) www.komen.org. Once logged on to any of the three sites, a toolbar allows easy access to the information on all three.

The site includes more than 100 pages of breast health information, areas designed for breast cancer survivors and their families, information on the Race for the Cure, and a calendar of breast cancer-related events and programs. Researchers can use the site to access applications for Komen Foundation grants.

A series of “Talk Back” sections encourage visitor participation and involvement by allowing users to share their first-hand experience with breast cancer.

Funds raised through the Lee National Denim Day in 1996 helped underwrite the website. The Lee Company invites corporations to participate by allowing their employees to wear denim to work on that day in exchange for a $5 contribution to the Komen Foundation.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content